Case no | Rheumatic diseases | Sex | Age (years) at LBCL diagnosis | Years from rheumatic disease symptoms to LBCL diagnosis | IPI | Bulk disease | c-MYC rearrangements | LBCL |
1 | pSS | F | 52 | 32 | Low/intermediate | + | − | DLBCL, NOS |
2 | pSS | F | 59 | 19 | Intermediate/high | NA | − | DLBCL, NOS |
3 | pSS | F | 53 | 18 | Low/intermediate | − | − | DLBCL, NOS |
4 | pSS | F | 48 | 38 | Low | NA | − | DLBCL, NOS |
5 | pSS | F | 83 | 22 | Intermediate/high | NA | − | DLBCL, NOS |
6 | pSS | F | 59 | 13 | Low | − | NA | DLBCL |
7 | pSS | F | 47 | 26 | High | − | – | DLBCL |
8 | pSS | F | 51 | 22 | High | NA | − | DLBCL, NOS |
9 | pSS | F | 39 | 6 | High | − | − | DLBCL, NOS |
10 | pSS | F | 62 | 15 | High | NA | NA | DLBCL, NOS |
11 | pSS | F | 45 | 22 | Intermediate/high | + | NA | DLBCL |
12 | pSS | F | 70 | 18 | High | − | NA | DLBCL |
13 | pSS | F | 73 | 18 | High | + | − | DLBCL |
14 | pSS | F | 73 | 24 | Intermediate/high | − | − | DLBCL, NOS |
15 | pSS | F | 67 | 15 | High | + | − | DLBCL, NOS |
16 | pSS | F | 30 | 3 | Low | − | − | DLBCL, NOS |
17 | pSS | F | 61 | 20 | Intermediate/high | − | − | EBV-positive DLBCL, NOS; monomorphic |
18 | pSS | F | 42 | 21 | Low/intermediate | − | NA | EBV-positive DLBCL, NOS; polymorphic |
19 | pSS | F | 43 | 22 | Low | NA | NA | THRLBCL |
20 | pSS | F | 57 | 14 | Intermediate/high | − | NA | THRLBCL |
21 | SLE and sSS | F | 61 | 25 | Low/intermediate | + | − | DLBCL, NOS |
22 | SLE and APS | F | 58 | 2 | Low | + | − | DLBCL, NOS |
23 | SLE | M | 60 | 5 | Intermediate/high | − | − | DLBCL, NOS |
24 | RA | F | 57 | 22 | Intermediate/high | − | − | DLBCL, NOS |
25 | RA and sSS | F | 62 | 19 | High | − | − | DLBCL, NOS |
26 | SSc and sSS | F | 59 | 26 | Low | − | − | DLBCL, NOS |
27 | SSc and sSS | F | 59 | 0 | Low/intermediate | − | NA | DLBCL |
+, positive; −, negative; APS, antiphospholipid syndrome; DLBCL, NOS, diffuse large B-cell lymphoma, not otherwise specified; EBV, Epstein-Barr virus; F, female; IPI, International Prognostic Index; LBCL, large B-cell lymphoma; M, male; NA, not available; pSS, primary Sjogren’s syndrome; RA, rheumatoid arthritis; SSc, systemic sclerosis; sSS, secondary Sjogren’s syndrome; THRLBCL, T-cell/histiocyte-rich large B-cell lymphoma.